C
Dosage Form: FOR ANIMAL USE ONLY
Centrine®
AMINOPENTAMIDE
HYDROGEN SULFATE
Veterinary Injection and Tablets
Centrine Description
Centrine (aminopentamide hydrogen sulfate) is a potent antispasmodic agent. As a cholinergic blocking agent for smooth muscle, its action is similar to atropine.
ACTION
Centrine effectively reduces the tone and amplitude of colonic contractions to a greater degree and for a more extended period than does atropine.
Centrine effects a reduction in gastric secretion, a decrease in gastric acidity and a marked decrease in gastric motility.
The mydriatic and salivary effects of Centrine are less than those produced by atropine at similar dosage, permitting the control of vomiting and diarrhea with less distress to the animal due to dryness of the mouth and blurred vision.
INDICATIONS
Centrine is indicated in the treatment of acute abdominal visceral spasm, pylorospasm or hypertrophic gastritis and associated nausea, vomiting and/or diarrhea.
Contraindications
Centrine should not be used in animals with glaucoma because of the occurrence of mydriasis.
Warning
FOR USE IN DOGS AND CATS ONLY.
Precautions
Dryness of the mouth is the most commonly reported side effect. Blurring of vision may occur and dryness of the eyes may occur if larger (greater than therapeutic) doses are used. Centrine should be used cautiously, if at all, in pyloric obstruction because of its action in delaying gastric emptying. These effects frequently decrease with continued administration of the drug. Disturbances in urination are relatively infrequent. They vary from slightly hesitancy in initiating urination to complete inability to urinate; the latter is an indication for discontinuing the drug. After a day or two, it may be resumed at a lower dosage level.
DOSAGE
Centrine (aminopentamide hydrogen sulfate) may be administered by subcutaneous or intramuscular injection or by oral tablets according to the following schedule. If the desired effect is not obtained, the dosage may be gradually increased up to a maximum of 5 times the doses listed. When the condition has been brought under control by parenteral medication, treatment can be continued, if desired, with 0.2 mg scored tablets according to the dosage schedule.
Weight of Animal
Amount to be Administered Every 8 to 12 hours
Dosage
Injectable Volume
Oral Tablets
10 lbs or less
0.1 mg
0.2 mL
1/2 Tab
11 lbs to 20 lbs
0.2 mg
0.4 mL
1 Tab
21 lbs to 50 lbs
0.3 mg
0.6 mL
1 1/2 Tabs
51 lbs to 100 lbs
0.4 mg
0.8 mL
2 Tabs
Over 100 lbs
0.5 mg
1.0 mL
2 1/2 Tabs
CAUTION
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
How is Centrine Supplied
0.5 mg/mL Centrine (aminopentamide hydrogen sulfate) VETERINARY INJECTION, 10 mL vials.
0.2 mg Centrine (aminopentamide hydrogen sulfate) VETERINARY TABLETS, bottles of 100.
NDC 0856-2401-10 – 0.5 mg/mL – 10 mL vials.
NDC 0856-2400-60 – 0.2 mg – bottles of 100.
Store at controlled room temperature 15° to 30°C (59° to 86°F).
Fort Dodge Animal Health
Fort Dodge, Iowa 50501 USA
92686
Rev. September 1996
4260F
NADA 43-079, Approved by FDA
NADA 43-078, Approved by FDA
PRINCIPAL DISPLAY PANEL - 10 mL Vial Label
NDC 0856-2401-10
Centrine®
AMINOPENTAMIDE
HYDROGEN SULFATE
Veterinary Injection
FORT DODGE®
contains 0.5 mg/mL
aminopentamide hydrogen sulfate
10 mL
CAUTION: Federal law restricts this
drug to use by or on the order of a
licensed veterinarian.
NADA 43-079, Approved by FDA
Centrine
aminopentamide sulfate injection, solution
Product Information
Product Type
PRESCRIPTION ANIMAL DRUG
NDC Product Code (Source)
0856-2401
Route of Administration
SUBCUTANEOUS, INTRAMUSCULAR
DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name
Basis of Strength
Strength
aminopentamide sulfate (aminopentamide)
aminopentamide sulfate
0.5 mg in 1 mL
Inactive Ingredients
Ingredient Name
Strength
No Inactive Ingredients Found
Product Characteristics
Color
Score
Shape
Size
Flavor
Imprint Code
Contains
Packaging
#
NDC
Package Description
Multilevel Packaging
1
0856-2401-10
10 mL In 1 BOTTLE
None
Marketing Information
Marketing Category
Application Number or Monograph Citation
Marketing Start Date
Marketing End Date
NADA
NADA043079
09/05/1970
Labeler - FDAH, Division of Wyeth (149957656)
Revised: 07/2010FDAH, Division of Wyeth
Centrine
.
